Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 12/20 | 0.70 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.63 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.62 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine 5'-Phosphate SCHEMBL29356502 | 0.94 | P2RX3 (0.69) | P2RY2P2RX3IMPDH2IMPDH1 | |
| Cytarabine 5'-Phosphate SCHEMBL29424346 | 0.94 | P2RX3 (0.69) | P2RY2P2RX3IMPDH2IMPDH1 | |
| Cytarabine 5'-Phosphate SCHEMBL27306 | 0.89 | P2RY2 (0.67) | P2RY2RNASELP2RY4P2RY6 | |
| Cytarabine 5'-Phosphate SCHEMBL19347100 | 0.88 | P2RY2 (0.85) | P2RY2P2RY4P2RY6 | |
| SCHEMBL29452474 | 0.88 | P2RX3 (0.65) | P2RY2RNASELP2RX3 | |
| Cytarabine 5'-Phosphate SCHEMBL29390918 | 0.86 | P2RX3 (0.59) | P2RY2P2RX3IMPDH2IMPDH1 | |
| E626 SCHEMBL16245477 | 0.85 | NT5E (0.71) | P2RY2P2RY4P2RY6IMPDH2IMPDH1 | |
| E626 SCHEMBL4299214 | 0.85 | P2RY2 (0.77) | P2RY2RNASELP2RY4P2RY6IMPDH2 | |
| SCHEMBL24160912 | 0.84 | P2RX3 (0.85) | P2RY2RNASELP2RX3IMPDH2IMPDH1 | |
| SCHEMBL18258283 | 0.84 | P2RX3 (0.85) | P2RY2RNASELP2RX3IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| EP-4719436-A1 | SYNERGY BETWEEN IFNalpha AND TLR3 LIGANDS IN SENSITIZING PD1-RESISTANT COLD TUMORS TO THERAPEUTIC EFFECTS OF PD-1 BLOCKADE | Health Research, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | Tets, Viktor Veniaminovich (US) | 2026-04-02 | — | — | US | claimed |
| US-20260000754-A1 | NANOPARTICLES AS CARRIER-SYSTEM FOR ADJUVANTS/ANTIGENS | UNIVERSITAT HEIDELBERG (DE) | 2026-01-01 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| WO-2025235998-A1 | PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNE MODULATORY ACTIVITY | IMMORTA BIO, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| US-12458622-B2 | Methods of treatment of coronavirus-induced inflammation conditions | THE GENERAL HOSPITAL CORPORATION (US) | 2025-11-04 | — | — | US | claimed |
| EP-4638443-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | claimed |
| CN-115282259-A | Oral spray preparation based on virus blocking agent and application thereof | 康码（上海）生物科技有限公司 | 2022-11-04 | — | — | CN | claimed |
| WO-2022229302-A1 | STRONG POTENTIATION OF TLR3 AGONISTS EFFECTS USING FXR AGONISTS AS A COMBINED TREATMENT | ENYO PHARMA (FR) | 2022-11-03 | — | — | WO | claimed |
| EP-4041195-A1 | COMPOSITIONS AND METHODS FOR PULMONARY SURFACTANT-BIOMIMETIC NANOPARTICLES | The General Hospital Corporation (US) | 2022-08-17 | — | — | EP | claimed |
| US-20220194951-A1 | DIHYDROPYRIMIDINE COMPOUND AND APPLICATION THEREOF AS DRUG | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-23 | — | — | US | claimed |
| WO-2022126207-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-06-23 | — | — | WO | claimed |
| WO-2022101619-A1 | A MYCOBACTERIUM FOR USE IN CANCER THERAPY | IMMODULON THERAPEUTICS LIMITED (GB) | 2022-05-19 | — | — | WO | claimed |
| WO-2022096896-A1 | MYCOBACTERIAL IMMUNOTHERAPY FOR TREATING CANCER | IMMODULON THERAPEUTICS LIMITED (GB) | 2022-05-12 | — | — | WO | claimed |
| WO-2022087471-A1 | SYNERGISTIC INDUCTION OF IMMUNITY AGAINST RNA VIRUSES | HEALTH RESEARCH, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| WO-2022082183-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF INFLAMMATORY AND METABOLIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | claimed |
| US-11261190-B2 | Dihydropyrimidine compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | P2RY2 3742/4885RNASEL 279/4885P2RY4 2052/4885 |
| US-20260000754-A1 | NANOPARTICLES AS CARRIER-SYSTEM FOR ADJUVANTS/ANTIGENS | TLR9, HLA-C, TLR3 | P2RY2 2872/4885RNASEL 2640/4885P2RY4 3282/4885 |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | ACE, MAVS, SARS1 | P2RY2 4114/4885RNASEL 216/4885P2RY4 2914/4885 |
| US-20220194951-A1 | DIHYDROPYRIMIDINE COMPOUND AND APPLICATION THEREOF AS DRUG | DHODH, DPYD, SLC10A1 | P2RY2 2599/4885RNASEL 2781/4885P2RY4 2114/4885 |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | PRNP, FUCA1, SNCA | P2RY2 1696/4885RNASEL 42/4885P2RY4 1705/4885 |
| US-12458622-B2 | Methods of treatment of coronavirus-induced inflammation conditions | C3AR1, IL5, IL4 | P2RY2 1373/4885RNASEL 291/4885P2RY4 526/4885 |
| US-11261190-B2 | Dihydropyrimidine compounds and uses thereof in medicine | DPYD, TPMT, SLC10A1 | P2RY2 1980/4885RNASEL 1975/4885P2RY4 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.